R J Fram
Overview
Explore the profile of R J Fram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
Conley B, Egorin M, Tait N, Rosen D, Sausville E, Dover G, et al.
Clin Cancer Res
. 1998 May;
4(3):629-34.
PMID: 9533530
Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin, a triglyceride with butyrate molecules esterified at the 1, 2, and 3 positions,...
3.
Glover D, Lipton A, Keller A, Miller A, Browning S, Fram R, et al.
Cancer
. 1994 Dec;
74(11):2949-55.
PMID: 7525038
Background: Treatment of the symptoms of bone metastases currently involves the use of narcotic medication, radiation therapy, or hormonal therapy. Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative...
4.
Fram R
Curr Opin Oncol
. 1992 Dec;
4(6):1073-9.
PMID: 1457521
Cisplatin is a critically important antineoplastic agent employed in treating patients who have a broad spectrum of neoplasms. Resistance to this agent poses a serious clinical dilemma. The objective of...
5.
Recht L, Fram R, Strauss G, Fitzgerald T, Liepman M, Lew R, et al.
Am J Clin Oncol
. 1990 Apr;
13(2):125-31.
PMID: 2156417
Thirty patients with histologically verified malignant supratentorial gliomas were treated with a preirradiation chemotherapy protocol consisting of two courses of intracarotid (i.c.) CDDP, 90 mg/m2, followed by i.v. BCNU, 200...
6.
Fram R, Robichaud N
Biochem Pharmacol
. 1990 Mar;
39(5):959-64.
PMID: 2155617
Streptozotocin (STZ) is a monofunctional nitrosourea employed in the treatment of patients with islet cell tumors. To analyze the role of DNA repair mechanisms in causing resistance to STZ, we...
7.
Fram R, Woda B, Wilson J, Robichaud N
Cancer Res
. 1990 Jan;
50(1):72-7.
PMID: 2293559
To study mechanisms underlying resistance to cis-diamminedichloroplatinum (II) (cis-DDP) we have induced resistance to this agent in BE human colon carcinoma cells. A 5-fold increase in the IC50 of resistant...
8.
Robichaud N, Fram R
Chem Biol Interact
. 1990 Jan;
76(3):333-42.
PMID: 2225234
We have found that the potentiation of antiproliferative effects by buthionine sulfoximine (BSO) of cell growth inhibition induced by cisplatin are highly schedule dependent in resistant BE colon carcinoma cells....
9.
Fram R, Mack S, George M, Marinus M
Mutat Res
. 1989 Sep;
218(2):125-33.
PMID: 2475773
Mechanisms underlying cytotoxicity by the monofunctional nitrosourea streptozotocin (STZ) were evaluated in DNA repair-deficient E. coli mutants. Strains not proficient in recombinational repair which lack either RecA protein or RecBC...
10.
Mack S, Fram R, Marinus M
Nucleic Acids Res
. 1988 Oct;
16(20):9811-20.
PMID: 2972994
The isolation and characterization of streptozotocin (STZ)-induced mutations in the phage P22 mnt repressor gene is described. Cells carrying the plasmid-borne mnt gene were exposed to STZ to give 10-20...